VYJUVEK® (beremagene geperpavec-svdt) (VYEJOO-VEK), developed by Krystal Biotech, is the first FDA-approved treatment to address the genetic cause of Dystrophic Epidermolysis Bullosa (DEB). It is a topical gel that delivers new COL7A1 genes directly to DEB skin wounds to promote wound healing.
Overview
|
EB Type |
Dystrophic Epidermolysis Bullosa | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Approved Age |
From Birth | |||||||||
|
Dose |
Dependent on age:
|
|||||||||
|
Preparation |
Prepare VYJUVEK gel at the pharmacy by mixing VYJUVEK biological suspension into the excipient gel for immediate use. | |||||||||
|
Administration |
The VYJUVEK gel prepared at the pharmacy, should be applied by a healthcare professional (HCP), patient, or caregiver either at a healthcare professional setting (e.g., clinic) or at a home setting. Apply VYJUVEK gel to the selected wound(s) in droplets spaced evenly within the wound, approximately 1cm-by1cm apart. |
|||||||||
|
How Often |
Applied once weekly | |||||||||
|
Adverse Reactions |
Most common adverse reactions were itching, chills, redness, rash, cough, and runny nose. | |||||||||
|
Prescribing Information |
Full Prescribing Information |
Getting Started
Whether you're considering treatment with VYJUVEK, ready to start, or looking for more information, Krystal Connect brought to you by Krystal Biotech is here to help you.
When you contact and enroll in Krystal Connect, you will be connected to a dedicated team. Your team is available to:
- Provide education about VYJUVEK and DEB
- Help you understand your insurance coverage through benefits investigation
- Inform you about financial assistance programs for eligible patients
- Support treatment planning and administration
- Provide information to help you locate a treating doctor in your area
Get Started with Krystal Connect at VYJUVEK.com
Or call 1-844-5-KRYSTAL
